Design, synthesis and biological activity of 1H-indene-2-carboxamides as multi-targeted anti-Alzheimer agents


KOCA M., Yerdelen K. O., ANIL B., Kasap Z., Sevindik H., Ozyurek I., ...Daha Fazla

JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY, cilt.31, ss.13-23, 2016 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 31
  • Basım Tarihi: 2016
  • Doi Numarası: 10.1080/14756366.2016.1186019
  • Dergi Adı: JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.13-23
  • Anahtar Kelimeler: AChE, Alzheimer, A1-42, BuChE, molecular modeling, AMYLOID-BETA, ANTICHOLINESTERASE ACTIVITY, MULTIFUNCTIONAL AGENTS, DISEASE, ACETYLCHOLINESTERASE, DERIVATIVES, DOCKING, ANALOGS, BUTYRYLCHOLINESTERASE, AGGREGATION
  • Erzincan Binali Yıldırım Üniversitesi Adresli: Evet

Özet

The aim of this study was to design new molecules and evaluate their anticholinesterase and amyloid beta (A(1-42)) inhibition activities as multifunctional drug candidates for the treatment of Alzheimer's disease (AD). A series of 5,6-dimethoxy-1H-indene-2-carboxamides (1-22) was synthesized; cholinesterase inhibitory activities of the compounds were measured according to Ellman's colorimetric assay, while the thioflavin T assay was used for measuring the inhibition of A(1-42) aggregation. The results revealed that most compounds showed higher inhibitory activity against BuChE than AChE. Compounds 20 and 21 were found to be the most potent BuChE inhibitors with respective IC50 values of 1.08 and 1.09M. Compounds 16, 20, 21 and 22 exhibited remarkable inhibition of A(1-42) aggregation. Kinetic analysis showed that the most potent BuChE inhibitor (20) acted as a noncompetitive inhibitor. Docking studies suggested that inhibitor 20 displayed many potential hydrogen-bondings with the PAS of BuChE. These results suggest that compound 20 may be an especially promising multifunctional drug for the prevention and treatment of AD.